{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T02:44:08Z","timestamp":1786157048058,"version":"build-2736575974"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Zhejiang Provincial Medical and Health Science and Technology Project","award":["2025KY706"],"award-info":[{"award-number":["2025KY706"]}]},{"name":"Zhejiang Provincial Medical and Health Science and Technology Project","award":["2022KY665"],"award-info":[{"award-number":["2022KY665"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The perioperative role of systemic therapy remains poorly defined in borderline resectable or unresectable non-head-and-neck locally advanced cutaneous squamous cell carcinoma (cSCC). We evaluated whether conversion-intent PD-1-based chemoimmunotherapy could restore surgical feasibility in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective cohort study included consecutive patients with non-head-and-neck locally advanced cSCC treated with conversion-intent PD-1 inhibitor plus taxane\/platinum-based chemotherapy between January 2022 and December 2025. The primary endpoint was conversion to surgical candidacy. Secondary endpoints included surgery, R0 resection, radiologic and pathologic responses, safety, and survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 28 included patients, 17 (60.7%) had unresectable disease at baseline. Following conversion-intent systemic therapy, 23 patients (82.1%) were considered eligible for surgery, and 22 (78.6%) underwent curative-intent surgery. R0 resection was achieved in 16 patients overall (57.1%) and in 72.7% of patients who underwent surgery. The objective response rate was 50.0%, the disease control rate was 89.3%, and the radiologic downstaging rate was 46.4%. Primary-site pathological complete response was observed in 18.2% of patients who underwent surgery. Treatment-related adverse events were common (85.7%), whereas grade \u22653 events were infrequent (14.3%), and permanent discontinuation and surgery delay each affected only a small minority of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Conversion-intent PD-1-based chemoimmunotherapy was associated with restoration of surgical feasibility in selected patients with borderline resectable or unresectable non-head-and-neck locally advanced cSCC. These findings support a conversion-oriented treatment approach and suggest that surgery-related endpoints may be more informative than radiologic response alone in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag252","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:17:07Z","timestamp":1785237427000},"source":"Crossref","is-referenced-by-count":0,"title":["Conversion-intent PD-1-based chemoimmunotherapy restores surgical feasibility in borderline resectable or unresectable non\u2013head-and-neck cutaneous squamous cell carcinoma"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-285X","authenticated-orcid":false,"given":"Wenkang","family":"Qian","sequence":"first","affiliation":[{"name":"Department of Bone and Soft Tissue, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences , Hangzhou, Zhejiang 310022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences , Hangzhou, Zhejiang 310022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences , Hangzhou, Zhejiang 310022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanhui","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences , Hangzhou, Zhejiang 310022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences , Hangzhou, Zhejiang 310022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2328-4336","authenticated-orcid":false,"given":"Tao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences , Hangzhou, Zhejiang 310022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"2026080722165241700_oyag252-B1","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.ejca.2024.115121","article-title":"An updated review of immune checkpoint inhibitors in cutaneous oncology: beyond melanoma","volume":"214","author":"Pham","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026080722165241700_oyag252-B2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005082","article-title":"Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma","volume":"10","author":"Ascierto","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026080722165241700_oyag252-B3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"2026080722165241700_oyag252-B4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaad.2017.10.007","article-title":"Guidelines of care for the management of cutaneous squamous cell carcinoma","volume":"78","author":"Kim","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2026080722165241700_oyag252-B5","doi-asserted-by":"crossref","first-page":"e35920","DOI":"10.1002\/cncr.35920","article-title":"Top advances of the year: developments of immunotherapy in cutaneous squamous cell carcinoma, 2023-2024","volume":"131","author":"Trinconi Cunha","year":"2025","journal-title":"Cancer"},{"key":"2026080722165241700_oyag252-B6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.suc.2024.11.011","article-title":"Updates in management for local regionally advanced squamous cell carcinoma","volume":"105","author":"Farrow","year":"2025","journal-title":"Surg Clin North Am"},{"key":"2026080722165241700_oyag252-B7","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41568-023-00583-5","article-title":"Advances in cutaneous squamous cell carcinoma","volume":"23","author":"Winge","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"2026080722165241700_oyag252-B8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s11523-021-00844-z","article-title":"Immune checkpoint inhibitors for advanced cutaneous squamous cell carcinoma: a systematic review with meta-analysis","volume":"16","author":"Mehta","year":"2021","journal-title":"Target Oncol"},{"key":"2026080722165241700_oyag252-B9","doi-asserted-by":"crossref","first-page":"100875","DOI":"10.1016\/j.lanepe.2024.100875","article-title":"Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG access protocol","volume":"39","author":"Verkerk","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026080722165241700_oyag252-B10","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol"},{"key":"2026080722165241700_oyag252-B11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026080722165241700_oyag252-B12","doi-asserted-by":"crossref","first-page":"113252","DOI":"10.1016\/j.ejca.2023.113252","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: part 2. treatment-update 2023","volume":"193","author":"Stratigos","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026080722165241700_oyag252-B13","volume-title":"FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma","author":"Administration USFaD","year":"2020"},{"key":"2026080722165241700_oyag252-B14","author":"U.S. Food and Drug Administration. FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma. 2019."},{"key":"2026080722165241700_oyag252-B15","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.23.02625","article-title":"Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent\/metastatic head and neck squamous cell carcinoma (KEYNOTE-B10): a single-arm phase IV trial","volume":"42","author":"Dzienis","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026080722165241700_oyag252-B16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40257-025-00995-z","article-title":"Perioperative systemic therapy for high-risk cutaneous squamous cell carcinoma","volume":"27","author":"Kimball","year":"2026","journal-title":"Am J Clin Dermatol"},{"key":"2026080722165241700_oyag252-B17","article-title":"Emerging indications for neoadjuvant systemic therapies in cutaneous malignancies","volume":"12","author":"Junior","year":"2024","journal-title":"Med Sci (Basel)"},{"key":"2026080722165241700_oyag252-B18","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1038\/s41591-025-03943-w","article-title":"Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial","volume":"31","author":"Breukers","year":"2025","journal-title":"Nat Med"},{"key":"2026080722165241700_oyag252-B19","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1470-2045(23)00459-X","article-title":"Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study","volume":"24","author":"Gross","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026080722165241700_oyag252-B20","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N Engl J Med"},{"key":"2026080722165241700_oyag252-B21","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","article-title":"Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026080722165241700_oyag252-B22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jaad.2025.09.098","article-title":"Perioperative treatment strategies for advanced melanoma and nonmelanoma skin cancers","volume":"94","author":"Sun","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"2026080722165241700_oyag252-B23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17040637","article-title":"Neoadjuvant immunotherapy in cutaneous squamous cell carcinoma: systematic literature review and state of the art","volume":"17","author":"Spadafora","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026080722165241700_oyag252-B24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26168109","article-title":"Efficacy of neoadjuvant cemiplimab treatment for cutaneous squamous cell carcinoma-a systematic review","volume":"26","author":"Palomba","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026080722165241700_oyag252-B25","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.bjoms.2022.01.006","article-title":"Validation of a post operative complication risk prediction algorithm in a non-head and neck squamous cell carcinoma cohort","volume":"60","author":"Reeves","year":"2022","journal-title":"Br J Oral Maxillofac Surg"},{"key":"2026080722165241700_oyag252-B26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/ajd.13739","article-title":"Cutaneous squamous cell carcinoma metastatic to the axilla and groin: outcomes and prognostic factors","volume":"63","author":"Bucknell","year":"2022","journal-title":"Australas J Dermatol"},{"key":"2026080722165241700_oyag252-B27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1440-0960.2009.00576.x","article-title":"Managing patients with cutaneous squamous cell carcinoma metastatic to the axilla or groin lymph nodes","volume":"51","author":"Goh","year":"2010","journal-title":"Australas J Dermatol"},{"key":"2026080722165241700_oyag252-B28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40257-025-00987-z","article-title":"Performance of staging systems for non-head and neck cutaneous squamous cell carcinoma","volume":"27","author":"Voller","year":"2026","journal-title":"Am J Clin Dermatol"},{"key":"2026080722165241700_oyag252-B29","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jdv.18147","article-title":"Histopathologic features predictive of metastasis and survival in 230 patients with cutaneous squamous cell carcinoma of the head and neck and non-head and neck locations: a single-center retrospective study","volume":"36","author":"Farah","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026080722165241700_oyag252-B30","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1200\/JCO-25-00387","article-title":"Response-adapted surgical and radiotherapy de-escalation in resectable cutaneous squamous cell cancer using pembrolizumab: the de-squamate study","volume":"43","author":"Ladwa","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026080722165241700_oyag252-B31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1001\/jamaoto.2024.0259","article-title":"Neoadjuvant-Intent immunotherapy in advanced, resectable cutaneous squamous cell carcinoma","volume":"150","author":"Kim","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag252\/70344507\/oyag252.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag252\/70344507\/oyag252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag252\/70344507\/oyag252.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T02:17:05Z","timestamp":1786155425000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag252\/8746787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag252","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,29]]},"article-number":"oyag252"}}